September 14 - 16, 2021 - Autogenous Vaccines Hybrid Meeting

Autogenous Vaccines Hybrid Meeting:
Quality of production and movement in a common market

Ludwig-Maximilians-University Munich


Registration and Information about the Meeting

There is a lack of vaccines ad us vet, as the existing licensing procedures within EU are demanding concerning the scientific requirements, the length, costs and complexity of procedures. Therefore, vaccines manufacturers tend to focus on the licensing and manufacture of products that have defined development pathways, demonstrated veterinary need, and reasonable expectations for a return on investment. As a consequence the market for autogenous vaccines to meet “niche” customer needs increased despite a minimally-regulated situation, especially in terms of manufacturing quality. There is no mutual recognition of GMP or GMP like certificates. Vaccination in general and in particular autogenous vaccines contribute to the use and reduction of antibiotics in food producing animals.

There are no harmonised provisions concerning the manufacture and control of autogenous vaccines, not to mention the non communication and non information of authorities concerning the movement of vaccines and vaccinated animals within the EU and beyond.

First attempt to harmonise some requirements was the CMDv paper on this item and now the revision of the vet legislation in EU.  

The meeting is intended to initiate productive conversations with manufacturers, competent authorities and users to develop a draft proposal how to form a common market which will improve overall disease control in the community, especially for diseases that suffer from a lack of conventionally-authorised products. The proposal should support the efforts of the French and Czech EU-Presidencies in 2022.

Key items will be: GMP /GMP-like requirements,  mutual recognition of inspections, import and export of autogenous vaccines, relevance and impact on diagnostics and the information on vaccinated animals whenever they are moved to allow an epidemiological surveillance.

Scientific Committee

Carmen Jungbäck IABS-EU, Germany
Klaus-Peter Behr Anicon, Germany
Gerfried Zeller EMAV, Germany
Peter Schmid CEVA, Germany
Dusan Palic LMU, Germany
Vaughn Kubiak IABS, France
Jiri Bures USKVBL, Czechslovakia
Mariette Salery ANSES, France
Jason Todd VMD, United Kingdom
Natalie Vasallo LABOCEA, France
Maarten De Gussem Poulpharm, Belgium
Iska Lehmann LAVES, Germany
Santiago Caballiero CETGA, Spain



Use the buttons below if you would like to share this info :

International Alliance for Biological Standardization

Twitter Feed

We wish all of our partners and friends a Great year 2022 !
Few more days to register to the IABS 7th Stats meeting: Accelerating Drug Development: How QbD, Regulatory Partner…
Follow IABS-Int. Alliance for Biological Standardization on Twitter

Contact Info

IABS, Rue Mina-Audemars, 3
CH-1204 Geneva

+ 41 22 301 10 36
This email address is being protected from spambots. You need JavaScript enabled to view it.